ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cytokines and Soluble Mediators in Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1604332
This article is part of the Research TopicBiomarkers and Beyond: Predicting Course and Tailoring Treatment in Inflammatory Bowel DiseasesView all 7 articles
IL-36/IL-36R Signaling Promotes CD4 + T Cell-Dependent Colitis via Pro-Inflammatory Cytokine Production
Provisionally accepted- Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Inflammatory bowel disease (IBD) is a multifactorial, chronic disease that affects approximately 1.5 million people in the United States. Several important factors are implicated in the pathogenesis of IBD, one factor being dysregulation of the immune system. This dysregulation results in the accumulation and stimulation of innate and adaptive immune cells, and subsequent release of soluble factors, including pro-inflammatory cytokines. One of these cytokines is a member of the IL-36 cytokine family, IL-36γ, which is overexpressed in human IBD and experimental models of colitis. In this study, we explored the role of IL-36γ in promoting CD4+ T cell activation and cytokine secretion.Methods: Spleens and lymph nodes were collected from wild-type and IFNγ-/- mice and were processed into cell suspensions to isolate naïve CD4+ T cells. Naïve CD4+ T cells were stimulated with IL-36 cytokines. IFNγ and TNFα were evaluated by ELISA using cell culture supernatants, and cell culture pellets were used to isolate RNA for qPCR. Naïve CD4+ T cells previously stimulated in the presence or absence of IL-36γ, from wild type (WT) or IFNγ-/- mice were transferred to Rag-/- mice to induce colitis. Fecal pellets were collected from mice during disease to analyze lipocalin (LCN2) levels from fecal supernatants. After euthanasia, colons, spleens, and mesenteric lymph nodes were harvested and processed into cell suspensions for intracellular cytokine staining.Results: Our results demonstrate that IL-36γ stimulation of naive CD4+ T cells significantly induced IFNγ expression in vitro and was associated with augmented intestinal inflammation in vivo using the T cell transfer model of colitis. Using IFNγ-/- naive CD4+ T cells, we observed a dramatic decrease in the ability of these cells to produce TNFα. Moreover, the transfer of these cells to Rag-/- mice did not cause robust colitis.Conclusion: These data not only suggest that IL-36γ is a regulator of a pro-inflammatory cytokine network involving IFNγ and TNFα but also highlights the importance of targeting IL-36γ and IFNγ as therapeutic approaches. Our studies have broad implications in relation to targeting specific cytokines in human IBD.
Keywords: inflammatory bowel disease, T cell mediated colitis, Adoptive Transfer, IL-36G, IFNg Signaling, Crohn's disease, ulcerative colitis
Received: 01 Apr 2025; Accepted: 11 Jun 2025.
Copyright: © 2025 Maarouf, Kuczma and Denning. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Maya Maarouf, Center for Inflammation, Immunity, and Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, 30303, Georgia, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.